Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALM014
- Development stage
- Unknown
- Lead developer
- Almatica Pharma
01
Overview
ALM014 is an investigational drug candidate being developed by Almatica Pharma, a subsidiary of Alvogen, for the treatment of depression. Currently in Phase 2 clinical development, ALM014 is part of Almatica's central nervous system (CNS) therapeutic portfolio, which focuses on psychiatric and neurological disorders. While the asset is actively progressing through clinical stages, Almatica Pharma has not publicly disclosed specific details regarding its molecular target, pharmacological mechanism of action, or chemical modality (e.g., small molecule). The drug is positioned as a proprietary candidate within the company's pipeline of CNS-focused treatments.
Beyond the preview
Go deeper on ALM014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALM014.